Skip to content
MarketScale
‹ Back to IndustriesSciences

How Basic Chemicals are Being Impacted in the Supply Chain

Key Points: Supply Chain Issues are causing disruptions to the chemical industry. Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions. The big players figured out how to deal with disruptions in the supply chain. Commentary: Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · Basic ChemicalsChemical Supply ChainPrice SurgePvc
Share

Key takeaways

01

Key Points: Supply Chain Issues are causing disruptions to the chemical industry.

02

Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.

03

The big players figured out how to deal with disruptions in the supply chain.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Request an invite

Key Points:

  • Supply Chain Issues are causing disruptions to the chemical industry.
  • Ethylene, PVC, and epoxy resins are seeing price surges to the disruptions.
  • The big players figured out how to deal with disruptions in the supply chain.

Commentary:

Disruptions in the supply chain are causing problems across every industry. Basic chemicals, such as ethylene, PVC, and epoxy resins, are seeing price surges due to these disruptions. We asked Jimmy Jett, CEO of Integrity BioChem, about these demand increases and what sort of role does it play in the overall chemical supply chain issue.

Abridged Thoughts:

Obviously, demand. There is a lot of pent-up demand from the pandemic, as people start to consume more and get back on the roads and travel. You’re seeing a lot of demand. It is unfortunate that demand is spiking, as supply is dwindling. What you’re seeing is that the big players have more sophisticated supply chain systems and have gotten out ahead of it. Some great examples are you’ve seen some of the bigger companies that have even contracted their own fleet to move goods and services around the world. You’re seeing some of the larger players with a really solid plan to mitigate some of the supply chain issues, but the Tier Two and Three companies might not have the cash flow to go out and purchase six months worth of inventory. 

What Can the Pharma Industry Learn from Merck’s New Antiviral?

Will Consumers Be Seeing Higher Prices as the Result of the Tightened Supply Chain?

Video TranscriptExpand ↓

Disruptions in the supply chain are causing problems across every industry. Basic chemicals such as ethylene, PVC and epoxy resins are seeing price surges due to these disruptions. With that in mind, we asked Jimmy, CEO of integrity biochim. About this increases in the man and what sort of role does it play in the overall chemical supply chain issue? You know, obviously demand there's a lot of pent up demand from the pandemic as people start to consume more and get back on the roads and travel. You're seeing a lot of demand, and it's unfortunate that demand is spiking as supply is dwindling. So what you're seeing is the big players that have a more sophisticated supply chain system have gotten out ahead of it. Some great examples or you've seen a lot of the bigger companies that have even contracted their own fleet to move goods and services around the world. And so you're seeing some of the larger players with a really solid plan to mitigate a lot of the supply chain issues. But the tier two and tier three companies that might not have the cash flow to go out and purchase six months worth of inventory are feeling it the most and you're going to see. And then the reality is in the US that tier two and tier three support system in manufacturing than in the chemical space that goods and services, it makes up a massive percentage of the market. So you're going to see a very compressed manufacturing base that are able to get the products. And so with that are going to come a lot of delays. You can just expect, you know, lead times to go from 2 to three weeks to six months and even pushed out further. So it's going to be interesting as the market tries to correct. We already know what these issues are doing to chemicals such as ethylene, PVC and epoxy resins. But what about the sustainable, bio based chemicals? Are they being impacted similarly or in a completely different way? So the sustainable supply chain, you know, the surfactants or the based surfactants and the chemical side have not been impacted. But what you're going to find is that a lot of the technology out there, you obviously don't have the production capacity that is built into their traditional synthetic market. So a lot of the fermentation capacity has come a long way and you're going to see them surge over the next six months because they're going to be able to produce what they can. However, what they can produce is just a fraction of what the industry needs. A lot of the vegetative sources like integrity biochem uses, they're going to be more readily available as well, but they're emerging technologies and they might not have the adoption that traditional synthetics have. So it's going to be interesting to see how quickly you can get these chemistries into the supply chain and through the regulatory side in an expedited way to make an impact. Finding solutions to these supply chain issues is something every industry is trying to figure out when it comes to chemical producers. What strategies should they implement westjet? Should they be investing in New supply chain partnerships, new chemical compounds or new production workflows? And this is what he had to say. I think it's definitely a mix. I mean, you have to be looking at alternative supply partners immediately to secure the pent up demand that is required to run your business. But, you know, in a congruent path, you need to be also looking at New technologies that might supplement or even replace some of these existing technologies. You know, one of the things I love about this industry is that innovation is born in difficult supply markets. When there's challenges out there, a lot of new stuff is developed and a lot of new markets are created. So I'm excited to see what happens. I mean, America is we are excellent at adapting. And so I think we're going to see a lot of neat new technologies emerge and a lot of sustainable products that might have been on the sidelines are going to have a shot to come in and replace some of the sympathetics that you just can't get right now. Chemical energy and its demands is something that needs to be closely evaluated, especially when it's in high demand and a supply chain process is facing as many issues as it is. For more stories of energy and its supply chain effects, be sure to head to Marcus gmail.com as well as subscribe.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech’s $750M Hillsboro build adds device fill-finish capacity by 2031

Genentech is investing $750 million in a new fill-finish plant in Hillsboro. The facility will focus on the production of prefilled syringes and autoinjectors. The site is expected to become operational in 2031.

  • 01Genentech is investing $750 million in a new Hillsboro facility.
  • 02The facility will produce prefilled syringes and autoinjectors.
  • 03Operations at the plant are expected to begin in 2031.

Aug 27, 2026

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio hpDNA in Genezen projects could cut AAV input DNA by 30%

4basebio's cell-free hpDNA will be used by Genezen as starting material for viral vectors, potentially reducing the need for AAV input DNA by 30%. This innovation may lead to changes in the specification of plasmids and project timelines in gene therapy programs.

  • 01Genezen will utilize 4basebio’s cell-free hpDNA for viral vector production.
  • 02This approach could reduce AAV input DNA requirements by 30%.
  • 03The adoption of hpDNA could lead to changes in plasmid specification and project timelines.

Aug 27, 2026

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers exits Cellares deal, putting standardized cell therapy capacity in doubt

Bristol Myers has terminated its agreement with Cellares, which raises concerns about the standardized capacity for cell therapy production. This decision highlights the importance of aligning manufacturing processes with production capabilities, rather than merely focusing on the availability of factory slots.

  • 01Bristol Myers has terminated its agreement with Cellares, affecting cell therapy capacity.
  • 02Aligning process fit with production capabilities is crucial for cell therapy success.
  • 03Factory slots alone are not sufficient to ensure supply plans in cell therapy production.

Aug 26, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512